Odyssey Therapeutics (ODTX) Q3 2026 earnings review
Odyssey advances its autoimmune pipeline, but trial spending climbs fast
Odyssey Therapeutics advanced its four autoimmune drug programs toward larger human studies while its research bill climbed fast. The biotechnology company spent $42 million on research and development, up 60% from a year ago, which widened its net loss excluding one-offs to $42 million. Chief executive Gary D. Glick presented new tissue and biomarker analyses for lead gut pill OD-001 and kept the cash runway target at the second half of 2028.
| Cash and marketable securities | $387M down $46M from last quarter by our math |
|---|---|
| Research and development spending | $42.1M +60% from a year ago |
| Net loss, excluding one-offs | $41.9M +46% from a year ago |
| Cash runway outlook | Unchanged funds operations into the second half of 2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because preclinical milestones arrived on schedule while the major clinical tests remain a year away. Finishing preclinical safety work for lupus candidate OD-002 and naming a candidate for OD-004 broaden the pipeline beyond gut disease. One caution: quarterly cash drain reached $46 million by our math, leaving almost no buffer below the $48 million quarterly pace implied by the 2028 runway plan, and the release did not confirm whether the next two OD-001 trials have started.
The question now is whether OD-001 can repeat its early open-label gut healing results in a larger trial with a placebo group while keeping spending inside the 2028 budget. Either the biomarker findings translate into clear placebo-adjusted remission in 2027, or rising trial bills force Odyssey to raise capital before those readouts finish. Topline data from the two OD-001 trials and the OD-002 volunteer study in the second half of 2027 will settle it.
🐂 Bull Case
Biomarker Data Back the Lead Gut Drug
Odyssey's lead medicine is OD-001, an oral pill that blocks RIPK2, a protein that drives gut inflammation. Chief executive Gary D. Glick said October data from 56 patients with moderate-to-severe ulcerative colitis showed symptom relief matched laboratory measures, "further reinforcing previously established clinical proof of concept in patients with ulcerative colitis". Tissue samples and inflammation markers moved in the same direction as patient symptoms.
Matching laboratory and tissue results matter in early autoimmune drug development because symptom scores alone can fluctuate. When gut tissue healing and gene activity line up with what patients report, it shows the pill is hitting its biological target in the digestive tract.
What to watch: topline results from the Phase 2b standalone trial and the Phase 2a combination study with vedolizumab, an existing gut antibody, in the second half of 2027. A clear statistical advantage over a control group would validate these early tissue findings.
Three Follow-On Autoimmune Drugs Move Forward
"Over the past several months, we have made meaningful progress across our entire pipeline," Glick said. The biotechnology group finished the preclinical safety studies required before human testing for OD-002, "a first-in-class oral SLC15A4 inhibitor" designed to calm overactive immune responses while "preserving normal host defense functions".
- OD-002 (oral immune pill for lupus): finished required preclinical studies; human trials start in the first half of 2027
- OD-003 (antibody designed to expand protective regulatory T cells): presenting preclinical data at the rheumatology conference in November 2026
- OD-004 (dual-target blocker of inflammatory proteins TSLP and IL-33): selected a formal development candidate for preclinical safety testing
Advancing three distinct programs reduces the US drug developer's reliance on its single gut medicine. Because OD-002 will test blood samples from healthy volunteers in an laboratory immune assay next year, investors will get an early biological read before full patient trials finish.
What to watch: healthy volunteer data for OD-002 in the second half of 2027. Strong immune blocking in those blood samples would support moving the pill into skin lupus patients.
🐻 Bear Case
Trial Spending Lifts Cash Burn to $46 Million
As a clinical-stage drug developer with no commercial products on the market, Odyssey funds its operations entirely from its cash reserves. The Boston-based group ended September with $387 million in cash and securities, down from $433.1 million in June, so it burned $46.1 million during the third quarter by our math.
- Third-quarter cash reduction: $46.1 million, up from $31.3 million in the second quarter by our math
- Research and development spending: $42.1 million, up 60.1% from a year ago and 16.3% from last quarter
- Net loss excluding one-offs: $41.9 million, up 46.0% from $28.7 million a year ago
Odyssey said the spending jump came from "higher external research and development costs associated with advancing the Company’s clinical and preclinical programs". By our math, stretching $387 million to the middle of the second half of 2028 leaves about $48.4 million per quarter, leaving almost no room for expenses to grow as larger trials begin.
What to watch: quarterly research and development expenses in the fourth-quarter report. A move above $45 million would push total quarterly cash burn past the pace needed to reach the second half of 2028.
Proof of Concept Rests on an Unblinded Trial
Glick emphasized that the October conference presentation reinforced clinical proof of concept across 56 evaluable ulcerative colitis patients, up from 49 patients reported in the first quarter. However, Odyssey did not publish the updated clinical remission or response percentages for the full 56-patient group in its third-quarter release.
In the first quarter, 49 patients showed a 27% remission rate and a 61% response rate. The company's risk disclosures note the "inherent limitations of an open-label trial without a concurrent placebo control", meaning every patient and doctor knew they were receiving the active drug, which often inflates symptom improvement in inflammatory bowel disease.
What to watch: the exact remission rate for all 56 patients in the upcoming quarterly filing or medical disclosures. A drop below the initial 27% mark would show the seven expansion patients fared worse.
Next-Stage Gut Trials Have Not Reported a Start
In both its first-quarter and second-quarter updates, Odyssey told investors it planned to start two new ulcerative colitis studies for OD-001 in the second half of 2026: a Phase 2b standalone trial and a Phase 2a combination trial with vedolizumab. Similarly, it previously planned to file a clinical trial application for OD-002 in the second half of 2026.
The November release dropped the second-half 2026 start targets from its milestone list without confirming that either OD-001 trial has dosed its first patient or that the OD-002 application has been filed. Management still expects topline data from both OD-001 trials in the second half of 2027, which compresses the window to enroll and treat patients.
What to watch: confirmation of first-patient dosing for the OD-001 Phase 2b trial before the end of 2026. If enrollment slips into 2027, the second-half 2027 readout target will likely move into 2028.
👓 Other Themes
Odyssey Promotes Insider to Chief Medical Officer
Odyssey appointed Dr. Anthony Opipari as chief medical officer and Laura Hare as chief people officer. Opipari joined the drug maker at its founding in 2021 and led the Phase 2a ulcerative colitis trial for OD-001, so his promotion keeps the same clinical leadership in place ahead of Phase 2b testing. Hare joins from CHARM Therapeutics to manage hiring and operations as the pipeline expands.
💲 Other KPIs
Employee equity grants rose 61.2% from $4.9 million a year ago and 38.6% from $5.7 million in the second quarter. Following its May initial public offering and new executive hires, Odyssey is paying a larger share of personnel costs in stock, which widens the accounting loss without using cash.
Overhead and administrative spending grew 9.8% from $10.2 million a year ago and 6.7% from $10.5 million last quarter, reversing two straight quarters of year-over-year declines. The biotech company said higher staffing costs and stock compensation drove the increase.
Odyssey recorded a $3.3 million non-cash accounting charge for potential future milestone payouts tied to past deals, up from $1.9 million a year ago but down from $8.7 million in the second quarter. Management strips this non-cash revaluation out of its operating loss measure.
🔮 Guidance
Unchanged. Odyssey expects its $387 million in cash and securities "to fund Odyssey’s operations into the second half of 2028", matching the timeline it set in the first and second quarters. By our math, funding the business across the eight quarters to the middle of that window allows an average burn of $48.4 million per quarter, just above this quarter's $46.1 million cash drain.
Unchanged. The drug developer still plans to report topline induction results from both its Phase 2b standalone study and its Phase 2a vedolizumab combination study in ulcerative colitis in the second half of 2027. Achieving this timeline requires rapid patient enrollment now that we are in the fourth quarter of 2026.
Unchanged on trial start, with a new data milestone added. Odyssey still plans to begin human testing of its oral SLC15A4 blocker in the first half of 2027, and newly guided for healthy volunteer blood-assay results in the second half of 2027 before expanding into skin lupus cohorts.
❓ Key Questions
Have the next two OD-001 gut trials started dosing?
Prior quarterly updates promised to start the Phase 2b standalone and Phase 2a combination trials in the second half of 2026. The November release dropped that start target without confirming whether enrollment has begun.
What was the remission rate across all 56 patients?
Odyssey reported a 27% remission rate for 49 patients in the spring, then expanded the analysis to 56 patients at the October conference without printing the updated remission percentage in the earnings release.
When will Odyssey file the trial application for OD-002?
Management finished preclinical safety studies for OD-002 on time, but removed the explicit second-half 2026 target for filing the regulatory application required to start human testing in early 2027.
How much will quarterly burn rise during Phase 2b?
Cash burn reached $46.1 million in the third quarter, leaving only $2.3 million of quarterly headroom against the $48.4 million average pace implied by the second-half 2028 cash runway target.